M

Medline Inc
NASDAQ:MDLN

Watchlist Manager
Medline Inc
NASDAQ:MDLN
Watchlist
Price: 43.19 USD 0.72%
Market Cap: $56.7B

Relative Value

There is not enough data to reliably calculate the relative value of MDLN.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MDLN Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

MDLN Competitors Multiples
Medline Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Medline Inc
NASDAQ:MDLN
56.3B USD 0 0 0 0
JP
Hoya Corp
TSE:7741
9.5T JPY 10.4 38 27.5 33
CH
Alcon AG
SIX:ALC
31.6B CHF 3.9 41.4 15.8 30.8
DK
Coloplast A/S
CSE:COLO B
103.9B DKK 3.8 26.4 13.7 16.4
US
Align Technology Inc
NASDAQ:ALGN
12.5B USD 3.1 30.5 13.2 18.1
UK
ConvaTec Group PLC
LSE:CTEC
4.9B GBP 2.7 37.6 14.8 25.4
CA
Bausch + Lomb Corp
NYSE:BLCO
6.3B USD 1.2 -17.1 17.8 57.6
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
40.7B CNY 9 24.8 22.4 22.4
JP
Asahi Intecc Co Ltd
TSE:7747
851.7B JPY 6.6 48.1 22.7 30.9
US
Lantheus Holdings Inc
NASDAQ:LNTH
4.9B USD 3.2 21 13.4 16.5
CH
Ypsomed Holding AG
SIX:YPSN
3.7B CHF 4.8 19.4 12.5 17
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
M
Medline Inc
NASDAQ:MDLN
Average EV/EBITDA: 17.4
Not Available
N/A N/A
JP
Hoya Corp
TSE:7741
27.5
12%
2.3
CH
Alcon AG
SIX:ALC
15.8
9%
1.8
DK
Coloplast A/S
CSE:COLO B
13.7
6%
2.3
US
Align Technology Inc
NASDAQ:ALGN
13.2
15%
0.9
UK
ConvaTec Group PLC
LSE:CTEC
14.8
13%
1.1
CA
Bausch + Lomb Corp
NYSE:BLCO
17.8
29%
0.6
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
22.4
13%
1.7
JP
A
Asahi Intecc Co Ltd
TSE:7747
22.7
11%
2.1
US
Lantheus Holdings Inc
NASDAQ:LNTH
13.4
N/A N/A
CH
Ypsomed Holding AG
SIX:YPSN
12.5
21%
0.6
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett